SOLID TUMORS

This study offers continued treatment with avelumab for people with advanced cancers like lung, ovarian, or bladder cancer who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug and monitor safety and survival. About 68 participants w…

This early-stage study tests a flavored, drinkable chemotherapy called VAL-413 (Orotecan) for children and young adults (ages 1-30) whose solid tumors have come back. The drug is given by mouth along with another chemo, temozolomide, for 5 days. The main goal is to find the safes…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a new antibody drug, acasunlimab, in people with advanced solid tumors that have not responded to standard treatments. The first part checks safety and finds the best dose, while the second part tests how well it works alone or with other cancer drugs. About 429 …

This early-stage study tests a new drug, MK-2870, alone or with pembrolizumab (and sometimes chemotherapy) in Japanese adults with advanced solid tumors or a type of lung cancer. The main goal is to check safety and find the right dose. About 30 people will take part.

This study tests whether giving cancer drugs based on the unique genetic changes in a person's tumor can shrink or control advanced solid cancers. About 920 adults and children with tumors that have spread or cannot be removed will receive a treatment chosen specifically for thei…

This study tests a drug called entrectinib in children and teens whose solid tumors or brain tumors have returned or haven't responded to other treatments. The drug targets specific gene changes (NTRK or ROS1 fusions) that help the cancer grow. The goal is to find the best dose a…

This early-stage trial tests an experimental drug called IMP321, which aims to boost the immune system's ability to fight cancer. It is given in new ways, such as direct injection into tumors or into the abdomen, and combined with other cancer treatments. The study includes 83 ad…

This early-stage study tests an experimental pill, ATV-1601, in people with advanced solid tumors (including certain breast, ovarian, and prostate cancers) that have a specific AKT1 gene mutation. The main goals are to check the drug's safety, find the best dose, and see how the …

This study gives patients with solid tumors continued access to the cancer drug pertuzumab if they were already taking it in a previous Roche-sponsored study and their doctor believes they are still benefiting. The goal is to monitor long-term safety and how well the drug control…

This early-stage study tests a new experimental drug (BI 770371) alone or with another drug (ezabenlimab) in adults with advanced solid tumors who have no other treatment options. The main goal is to find a safe dose and check for side effects. Participants receive infusions ever…

This early-stage study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the right dose…

This study tests the safety and effectiveness of the drug pembrolizumab in preventing cancer from returning in people who have had a solid tumor surgically removed but still have traces of tumor DNA in their blood. Participants receive pembrolizumab or a placebo for up to 12 mont…

This early-phase trial tests a new drug called BI-1910, alone or with pembrolizumab, in people with advanced solid tumors (like lung or liver cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug s…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or control the disease. About 253 adults will take part in this e…

This early-stage study tests a new drug called M9140 in 12 Chinese adults with advanced colorectal cancer that has not responded to standard treatments. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. The main goals are to check safety a…

This early-phase study tests a new drug, JSI-1187, alone or with another drug (dabrafenib) in people with advanced solid tumors that have certain gene changes (MAPK pathway mutations). The main goal is to check safety and side effects. About 71 adults with tumors that have not re…

This early-phase study tests an experimental mRNA vaccine (mRNA-4157) designed to help the immune system recognize and fight solid tumors. About 161 participants with certain cancers or at high risk of recurrence will receive the vaccine alone or with the immunotherapy drug pembr…

This early-phase study tests a new drug called runimotamab, given alone or with another drug (trastuzumab), in people with advanced HER2-positive cancers that have spread. The main goal is to check safety and how the drug moves through the body. About 123 adults with solid tumors…

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in adults with advanced solid tumors that cannot be cured. The main goal is to check safety and how the drug moves through the body. About 195 participants will take pa…

This early-phase study tests a new experimental drug, BI 1831169, in adults with advanced solid tumors that have spread or come back. The drug is given alone or with an immunotherapy (anti-PD-1 antibody) to find the safest dose and see if it can shrink tumors. About 190 participa…

This early-stage study tests an experimental drug called INCB186748 in 30 adults with advanced or spreading solid tumors that have a specific genetic mutation (KRAS G12D). The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participan…

This early-phase study tests a new treatment for children and young adults with high-risk solid tumors that have not responded to standard therapy. The approach uses a patient's own immune cells, trained to recognize multiple cancer targets, to attack the tumor. The main goal is …

This early-phase study tests a combination of two drugs (palbociclib and gedatolisib) in people with advanced lung, pancreatic, head & neck, or other solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drugs can slow can…

This early-stage study tests a new treatment called GK01 cell injection combined with a PD-1 monoclonal antibody for people with advanced solid tumors that have spread or come back. The main goal is to check safety and how the body handles the treatment, with a small group of 15 …

This early-phase study tests a new drug called GS-9911, given alone or with an immunotherapy drug, in 45 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. This is a first step to see if the a…

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…

This study tested whether the steroid dexamethasone can reduce common symptoms like fatigue, pain, nausea, and poor appetite in people with advanced solid tumors. About 132 participants took the drug and reported their symptom levels over two weeks. The goal was to improve daily …

This study looked at whether ginseng can help control fatigue and related symptoms like depression and anxiety in people with advanced cancers. 165 adults with solid tumors who had daily fatigue for at least two weeks took either ginseng or a placebo for 29 days. Researchers meas…

This study looks at the safest amount of aerobic exercise for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. It tests different exercise doses done at home using apps and devices. The goal is to see if exercise is feasible and what eff…

This early-phase study looks at how the antibiotic rifampicin changes the way the body handles the experimental cancer drug cediranib. It involves 64 adults with advanced solid tumors that have not responded to standard treatments. The goal is to understand drug interactions, not…

This study tests two different oral forms of the drug AZD2281 in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form, not to cure the cancer. About 197 participants will receive both forms i…

This study follows up to 500 children who have received gene therapy for cancer to monitor for any delayed side effects over 15 years. Participants will have regular blood tests and health check-ups. The goal is to better understand the long-term safety of these treatments.

This study collects blood samples from people who have unexpected or severe side effects from drugs they are taking as part of another NIH trial. The goal is to measure drug levels in the blood to better understand why side effects happen in some people but not others. Up to 100 …

This study collects leftover tissue and blood samples from people with known or suspected cancer who are already scheduled for surgery or biopsy. Researchers will compare cancerous and normal tissues to find differences that could lead to new treatments. No extra procedures are d…

This study aims to learn why certain solid tumors become resistant to targeted therapies. Researchers will collect blood, saliva, and tumor tissue from 2500 people with various cancers, including breast, lung, and colorectal cancer. The samples will be analyzed for genetic change…